NVO Novo Nordisk A/S Loading... NONOF

From BDX earnings calls
Loading chart...
Top Calls
Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
0 selected
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
All directions✓
▲ Long✓
▼ Short✓
⛔ Avoid✓
✂ Close✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
12:00
May 07 ◎
Tom Poland Chairman, CEO and President, Becton, Dickinson and Company BDX Q2 FY26 call
BD has signed over 80 GLP-1 biosimilar deals that will use its devices, with auto-injectors/pens carrying several times the ASP of syringes, making biosimilars a higher-value opportunity than the current novel GLP-1 market. — As GLP-1 biosimilars enter the market, BD's per-dose economics will improve substantially, making it a key supplier to the coming biosimilar wave and a hedge against oral GLP-1 disruption.
NVO
MED

About NVO Analyst Coverage

Buzzberg tracks NVO (Novo Nordisk A/S) across 1 sources. 0 bullish vs 0 bearish calls from 1 analysts. Sentiment: evenly split. 1 total trade idea tracked. Latest voices: Tom Poland.